Tuesday, September 19, 2017 9:53:52 AM
As such, no one here can tell you "how much" as that is based on the value of the patent claims remaining
Many here take offence to the reality that no one here has any clue as to that value because no one here has the skill set and experience to be a court appointed patent expert witness - one would need that level of knowledge to answer your question
As such, one should look to the collective knowledge of the market as within the market such expertise exists in numerous institutional patent investment groups
The fact those groups are not buying is an indictment on the value of the remaining claims as I have explained over and over
The market is valuing the remaining claims at zero. Many here believe they understand patents and patent law better than the market yet have no "real" experience in the sector - good on them!
I do not assume to have knowledge I do not have, and if the market values a a company's claims remaining in a very challenging sector to understand at zero, I listen and don't fool myself into thinking I know more. Ignoring what the market is telling you when you don't like it is called cognitive dissonance- not a smart way to invest.
You can disagree with the market, but disagreeing with the market because of your position vs KNOWING DETAILS OF PATENT TECH AND PATENT LAW AND THUS "WHY" are 2 very different beasts. There is no one here who disagrees w the market because they have insight, they disagree because they own the stock and don't like what the market is saying. That is not intelligent investing imho.
Until and unless a material amount of claims are recouped on appeal I would not touch this. Material number as I, nor anyone here can even know materiality, so the closer to the full amount of claims recouped the easier it is to assume that they have some value.
At that point it's an ok gamble.
Until then, especially with dilution coming and the market valuing the claims at zero I would never buy it
Recent WDDD News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 09:30:21 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 06:34:14 PM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • BLO • Apr 25, 2024 8:52 AM